Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Steven Rowsey"'
Autor:
Patrick Roth, Susan Moran, Ge Wei, Francesca Avogadri, Cindy Xu, Steven Rowsey, Harris S. Soifer, Pierre Giglio, Cristóbal Belda-Iniesta, Morris D. Groves, Paul M.J. Clement, Nicholas A. Butowski, Patrick Y. Wen, Filip Y.F. De Vos, Jeffrey J. Raizer, Vinay K. Puduvalli, Miguel J. Gil-Gil, Timothy F. Cloughesy, Juan Manuel Sepúlveda-Sánchez, Andrew B. Lassman
Supplementary Table from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e62bc045083f295b5505a4d2ceb22bf
https://doi.org/10.1158/1078-0432.22483670.v1
https://doi.org/10.1158/1078-0432.22483670.v1
Autor:
Patrick Roth, Susan Moran, Ge Wei, Francesca Avogadri, Cindy Xu, Steven Rowsey, Harris S. Soifer, Pierre Giglio, Cristóbal Belda-Iniesta, Morris D. Groves, Paul M.J. Clement, Nicholas A. Butowski, Patrick Y. Wen, Filip Y.F. De Vos, Jeffrey J. Raizer, Vinay K. Puduvalli, Miguel J. Gil-Gil, Timothy F. Cloughesy, Juan Manuel Sepúlveda-Sánchez, Andrew B. Lassman
Purpose:FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4433b4500bfad782b57ee3a0f26473dc
https://doi.org/10.1158/1078-0432.c.6531203
https://doi.org/10.1158/1078-0432.c.6531203
Autor:
Patrick Roth, Susan Moran, Ge Wei, Francesca Avogadri, Cindy Xu, Steven Rowsey, Harris S. Soifer, Pierre Giglio, Cristóbal Belda-Iniesta, Morris D. Groves, Paul M.J. Clement, Nicholas A. Butowski, Patrick Y. Wen, Filip Y.F. De Vos, Jeffrey J. Raizer, Vinay K. Puduvalli, Miguel J. Gil-Gil, Timothy F. Cloughesy, Juan Manuel Sepúlveda-Sánchez, Andrew B. Lassman
Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1563a5aa4a79c34480a823bb1d174a04
https://doi.org/10.1158/1078-0432.22483673
https://doi.org/10.1158/1078-0432.22483673
Autor:
Andrew B. Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, Miguel J. Gil-Gil, Vinay K. Puduvalli, Jeffrey J. Raizer, Filip Y.F. De Vos, Patrick Y. Wen, Nicholas A. Butowski, Paul M.J. Clement, Morris D. Groves, Cristóbal Belda-Iniesta, Pierre Giglio, Harris S. Soifer, Steven Rowsey, Cindy Xu, Francesca Avogadri, Ge Wei, Susan Moran, Patrick Roth
Publikováno v:
Clin Cancer Res
Purpose: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1992e8a27b1403d69013c5615f19e6fc
https://www.zora.uzh.ch/id/eprint/230044/
https://www.zora.uzh.ch/id/eprint/230044/